Search results: (10000)
News Turoctocog Alfa in Tertiary Prophylaxis of Hemophilia A or Is It Always About Bleeding? Case Studies
This case report from our own practice concerns our experience with the treatment of hemophilia A with turoctocog alfa. The intention is, among other things, to compare different outcomes in our two patients regarding their self-assessment of bleeding without objective validation.
News Comparison of the Efficacy of Tofacitinib and Vedolizumab in the Treatment of Ulcerative Colitis After Anti-TNF Therapy Failure
Therapeutic options for ulcerative colitis resistant to anti-TNF-α antibody treatment are available, but there were no studies comparing the selective immunosuppressants tofacitinib and vedolizumab in this patient population. The aim of this comparison was a multicenter French study, the first results of which were presented at the 17th ECCO Congress 2022.
News Risk of Venous Thromboembolism and CV Events during Targeted Treatment of Nonspecific Bowel Inflammations
Authors of a freshly published study based on real-world data from the USA investigated whether there are differences in the risk of venous thromboembolism (VTE) and major cardiovascular (CV) events in patients with nonspecific bowel inflammations (IBD) who were newly prescribed the Janus kinase inhibitor (JAK) tofacitinib or the tumor necrosis factor-alpha (TNF-α) inhibitor.
News Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population
Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does not spare individuals with hemophilia. According to epidemiological data, the prevalence of obesity is also increasing in this population, causing a number of complications in many health aspects.
News Doc. Petr Dulíček: Physical activity in hemophiliacs? Today it is a reality - just don't be afraid!
Thanks to modern treatment, the lives of hemophiliacs are becoming more active. Patients today can engage in most sports activities. On the contrary, avoiding physical activity carries the risk of developing other diseases. A doctor should support their patients so they are not afraid of physical activities and highlight their benefits, says the head of the Center for Hemostasis Disorders at the IV. Internal Hematology Clinic of LF UK and FN Hradec Králové, Doc. MUDr. Petr Dulíček, Ph.D., in an interview on hemophilia and sports.
News Tofacitinib Helps Restore Intestinal Epithelial Barrier
The Janus kinase inhibitor (JAKi) tofacitinib was relatively recently approved for the treatment of ulcerative colitis, but its effect on the intestinal epithelium remains a subject of research. The objective of the study presented below was to determine how tofacitinib aids in the repair of the cytokine-damaged intestinal epithelial cell barrier.
News Maintenance of Remission with Tofacitinib in Patients with UC – Results of the OCTAVE Open Study
Tofacitinib is indicated for the treatment of ulcerative colitis (UC) in cases where conventional treatment or monoclonal antibodies do not yield sufficient results. Key benefits of this medication include oral administration and predictable kinetics. The long-term efficacy of tofacitinib was studied in the OCTAVE Open study.
News Safety and Efficacy of Long-term Tofacitinib Therapy in Patients with Active Psoriatic Arthritis – Interim Results of the OPAL Balance Study
Tofacitinib is a potent selective inhibitor of the Janus kinase (JAK) family indicated for the treatment of active psoriatic arthritis in adult patients. The efficacy and safety of tofacitinib in this population have been verified for 6 and 12 months through clinical studies OPAL. A study published in 2020 presents interim results of the extended phase of these studies, evaluating its efficacy and safety in the long term.
News Cardiovascular Safety of Tofacitinib in Real-World Clinical Practice – Results of the STAR-RA Study
Recent results from the ORAL Surveillance clinical trial have raised concerns about the cardiovascular adverse effects of tofacitinib in patients with rheumatoid arthritis. A comprehensive analysis of real-world clinical practice data, involving nearly 13,000 patients, focused on the cardiovascular safety of tofacitinib for this indication.
News Cost-Effectiveness of Eletriptan in Acute Migraine Treatment
Even in a market dominated by generics, eletriptan 40 mg is among the most clinically effective and cost-efficient triptans for the acute treatment of migraine attacks. This was demonstrated by a systematic literature review focused on the pharmacoeconomic evaluation of this therapy, published by American authors in 2015. Its high cost-effectiveness may be due to its strong efficacy with a reduced need for additional treatment.
News Three tests to confirm the diagnosis of acquired hemophilia – infographic
Acquired hemophilia (AHA) typically manifests with spontaneous bleeding in patients with no prior personal history of significant bleeding.1–4 The cause of the bleeding is a significant decrease in FVIII activity induced by autoantibodies against coagulation factor VIII.5 In polymorbid patients, established antithrombotic therapy at the time of AHA diagnosis may also contribute to the bleeding.4
News Metformin in Pregnancy and Its Safety Profile
In Finland, a comprehensive analysis of data from the national registry was conducted to assess whether exposure to metformin during intrauterine development is associated with an increased risk of long-term or short-term health problems.
News Levothyroxine Substitution Depending on Patient Genotype
Careful titration of hormone dose leads to optimal dosing of replacement therapy for hypothyroidism. The authors of a cross-sectional study published in the Endocrine Journal examined the impact of polymorphisms in genes for proteins involved in thyroid hormone metabolism on the response to levothyroxine treatment in patients after thyroidectomy.
News Safety and Efficacy of Bimekizumab Self-Administration in Psoriasis Patients
Patient adherence to regular administration of biologic therapy is crucial for its effectiveness. The studies presented below evaluated self-administration of the humanized monoclonal antibody against IL-17A and IL-17F, bimekizumab, in patients with plaque psoriasis using a prefilled syringe or autoinjector.
News Comparison of the effects of fibrinogen concentrates and fresh frozen plasma in patients with acute traumatic coagulopathy
A quasi-experimental study compared the effectiveness of fibrinogen concentrates and fresh frozen plasma in patients with severe blunt trauma requiring the administration of erythrocyte replacements.